U.S. Markets closed

Curis, Inc. (CRIS)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
1.69-0.07 (-3.98%)
At close: 4:00PM EDT

1.69 0.00 (0.00%)
After hours: 4:45PM EDT

People also watch
ARQLCERSAGENARRYCYTR
  • M
    Mario
    Mario
    1.85. It is official (SEC Filings).
  • P
    Peter
    Peter
    Hate to be a debby downer but this stock is head to $1. No revenue in sight as 907 has been set back and Curis must raise money to stay afloat. Since it obtained approval of Erivedge back in January 2012 the stock has been a disaster.
  • D
    David
    David
    No doubt private investors got a 20% discount to the $2.02 close yesterday. Once the POS CEO Ali and the rest of the POS BOD fill in the blanks, (prospective) we will watch the share price sell off another .20 tomorrow

    Add on went off at $1.60, Ali and the BOD efinsuck
  • P
    Peter
    Peter
    Can we learn anything at CITC in earlyj November about clinical profile of CA-170 that we did not learn from the poster presentation at ESMO? What is the next catalyst? I wonder who Baird got to buy the 20,000,000 share offering.
  • K
    Kenneth
    Kenneth
    Results sound very promising.
  • D
    David
    David
    $1.60 ....Camel boy sold us out!
  • D
    David
    David
    Before Ali became CEO, he was previously appointed cleaner of the camel dung

    Then the camel bag holder

    Then on to CEO

    This entire management team from the BOD to operations including the CEO must go immediately before they destroy share holder value in its entirety!
  • P
    Peter
    Peter
    Public Offering Price
    $ 1.85 $ 37,000,000
    Underwriting Discounts and Commissions (1)
    $ 0.07 $ 1,400,000
    Proceeds to Curis before expenses
    $ 1.78 $ 35,600,000

    (1) The underwriter will be reimbursed for certain expenses in this offering. See “Underwriting” for details.
    Delivery of the shares of common stock is expected to be made on or about September 18, 2017. We have granted the underwriter an option for a period of 30 days to purchase up to 3,000,000 additional shares of our common stock. If the underwriter exercises this option in full, the total underwriting discounts and commissions payable by us will be $1,610,000 and the total proceeds to us, before expenses, will be $40,940,000.
  • T
    T
    T
    share price rose nearly 54% from its August low to Friday's high (80 cents, bottom to top). Close today down 27 cents from Friday's high. whatever the disappointment that there wasn't some kind of blowout positive news today, it seems likely that today's retreat involved "sell the news" and it wasn't extreme relative to the runup.
  • P
    Peter
    Peter
    reminds me of ph 1 preliminary results of 907, street deemed them underwhelming; only Curis can manage to disappoint on a day the stock market is soaring; as usual results not strong enough to trigger a major upswing and they need to raise some capital asap. Any postiive analysis would be welcome.
  • D
    David
    David
    Thanks
  • D
    David
    David
    You suck Ali, step down and let someone that know anything Ron the company

    Go back to the camel farm
  • s
    shalom
    shalom
    ESMO DATA
    Ali said at the Baird conference that we are getting ca170 data on monday. also said they will provide an update at SITC in Nov. I cant tell from his tone in the baird conference but seems like we have activity. listen to audio at about 24:45 he says they do chew away at tumor. good luck next week
  • K
    Ken
    Ken
    Business wire reported phase 2 trials performed in US, SOUTH KOREA, and soon INDIA. Results vary based amounts of medicine used and cancer conditions of patients.
  • J
    Joe
    Joe

    -- Results from 34 Patients Demonstrate Positive Safety Profile and Support Decision to Expand Development --

    -- Aurigene and Curis Plan Clinical Trial of CA-170 in India --

    LEXINGTON, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today presented preliminary data from the initial 34 patients with cancer treated in the dose escalation stage of the Phase 1 trial of CA-170 conducted in the U.S., South Korea and Spain, at the European Society for Medical Oncology (ESMO) 2017 Congress. As a result of the initial safety data and preliminary evidence of clinical benefit observed in the trial, Curis’s collaborator and discoverer of CA-170, Aurigene Discovery Technologies Limited, a specialized biotechnology company engaged in discovery and early clinical development of novel and best-in-class therapies to treat cancer and inflammatory diseases, today announced plans to initiate a Phase 2 trial of CA-170 to be conducted at sites in India.

    “We are pleased with these early results. Based on evidence of tumor shrinkage, multiple patients remaining on drug treatment for extended periods, and compelling signals for biomarkers of immune modulation in patient blood and tumor samples, we remain highly confident that the CA-170 program is moving in the right direction. We plan to continue with the dose escalation and continued analysis of patient biopsy samples in the Phase 1 trial,” said Ali Fattaey, Ph.D., President and Chief Executive Officer of Curis. “We expect to provide additional updates at upcoming conferences including the Society for Immunotherapy of Cancer (SITC) annual meeting in November.”

    “The ability for cancer patients to administer a potential checkpoint inhibitor on their own as a once daily oral drug is a significant and unique opportunity in our field,” added Adil Daud, M.D., investigator in the CA-170 Phase 1 trial and director of Melanoma Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center. “These initial clinical results are encouraging and merit continued development.”

    “These results are consistent with the observations made in the preclinical setting and further affirm CA-170’s mechanism of action as an oral small molecule checkpoint inhibitor,” commented Mr. CSN Murthy, Chief Executive Officer of Aurigene. “Based on these initial clinical results, we are excited for the opportunity to expand testing of CA-170, possibly in earlier lines of treatment and in a greater number of immunotherapy treatment-naïve cancer patients.” Added Mr. Murthy, “Together with Curis, we have designed a Phase 2 trial in selected populations of patients of interest to be treated at major cancer centers in India. Aurigene’s decision to sponsor and fund this trial is further affirmation of our commitment to CA-170 and a reflection of the successful collaboration we have with Curis in multiple development programs.”

    CA-170 is an oral small molecule targeting the immune checkpoints PDL1 and VISTA. Data presented at the ESMO 2017 conference represent the initial 34 patients treated to date in the dose escalation Phase 1 trial. 30 patients were naïve to prior immunotherapy treatment, while four patients had experienced prior treatment with approved anti-checkpoint antibodies. No dose limiting toxicities were observed at doses ranging from 50 mg to 800 mg once daily dosing examined thus far. CA-170 demonstrated good oral bioavailability and plasma drug levels were shown to increase in a near-linear manner with increasing doses. Evidence of immune modulation, including an increase in activated CD8+ T cells, was observed in patient blood and tumor biopsy samples examined following treatment. Of the 21 patients evaluable for disease assessment, 13 patients experienced disease stabilization. Four immunotherapy treatment-naïve patients treated with CA-170 experienced shrinkage of their tumors. Six patients remained on drug treatment beyond three months, including all four patients with tumor shrinkages. In addition, seven of the 34 patients remain on study and are continuing with treatment.

    About Curis

    Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. For more information, visit Curis's website at www.curis.com.

    Curis Inc. - Curis, Inc
    Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer.
    www.curis.com.
  • T
    T
    T
    today bought shares at 2.20 and sold a bunch of Sept 2.50 calls (for .30) and also some 5.00 calls (for .10). Implied volatility through the roof. (i.e., big premiums for 7 days to expir.) . How bad can that be?
  • P
    Peter
    Peter
    Excerpt abstract; not sure what is taking place at ESMO on 9/11 other than display of poster; assume there is some discussion of content of poster but no indication that Curis representative will be speaking.

    "Results

    CA-170 rescues in vitro T cell effector function with activity comparable to that of PD-1 or VISTA blocking antibodies. Oral CA-170 inhibits the growth of mouse syngeneic tumors (B16 melanoma, CT26 and MC38 colon carcinoma), enhances peripheral T cell activation, and promotes the activation of tumor infiltrating CD8+ T cells in vivo. In humans, a total of 19 patients have been treated across 6 dose levels (50 - 800 mg). No dose limiting toxicity has been observed. CA-170 exhibits generally dose proportional plasma exposure with T1/2 of ∼ 4-9.5 hours. Evidence of peripheral T cell activation was observed with an increased proportion of circulating CD8+ and CD4+ T cells expressing activation markers, CD69 and CD134, following oral dosing.

    Conclusions

    These pre-clinical and preliminary clinical PD data warrant the continued clinical development of CA-170, the first oral, small molecule immune checkpoint antagonist for the treatment of advanced cancers. Dose escalation is currently ongoing (NCT02812875)."
  • j
    john
    john
    MANIPULATED POS
  • M
    Mccgolf
    Mccgolf
    So comments on the poster anyone?
  • T
    T
    T
    Vanguard added 5 million shares (opening position) in Q2; listed in their 8/24 filing